[ad_1]
The AstraZeneca vaccine against C ovid-19 developed by the University of Oxford and the Pomezia Oxford-Astra-Zeneca Irbm highly effective in preventing the disease according to the preliminary results of clinical trials carried out in the United Kingdom and Brazil arrived in the phase 3 and communicated by the pharmaceutical company on Monday morning. The researchers explained that the vaccine works with a protection of 70%, therefore less than the 90% advertised by Pfizer and Moderna. However, protection appears to vary by dose. In addition, this vaccine is cheaper and easier to store than the other two and it will be able to reach any corner of the world more easily.
Dose
More than 20 thousand volunteers, half in the UK, the rest in Brazil. There were 30 cases of Covid among people who had received two doses of the vaccine and 101 among those who had received a placebo. What came up? When the volunteers received two full doses, the protection was 62% while one half the dose, followed by the full dose resulted in 90% protection. Combined analysis of both doses resulted in a mean efficacy of 70%. Protection begins no earlier than two weeks after inoculation of the second dose (one month after the first). No serious adverse events related to the vaccine were identified and serum was well tolerated in both dosing regimens even by the elderly population. From the first data communicated by the pharmaceutical company and not yet published in scientific journals, it thus emerges that Therefore, the optimal administration regimen is half a dose with a full booster dose after one month..
Important milestone against the pandemic
Today marks an important milestone in our fight against the pandemic. The efficacy and safety of this vaccine confirm that it will be very effective against Covid-19 and will have an immediate impact on this public health emergency. In addition, the vaccine’s simple supply chain and our non-profit commitment to broad, fair and timely access means it will be affordable and available globally, delivering hundreds of millions of doses once approved. Pascal Soriot, CEO of Astrazeneca. The results – add Andrew Pollard, Lead Investigator of the clinical study, we show that we have an effective vaccine that will save many lives. Interestingly, we find that one of our dosing regimens can be around 90% effective and if this mode of administration is used, more people could be vaccinated with the intended vaccine.
Protected the elderly
The results of the first phase 2-3 data were published in The Lancet last week and the results suggested that one of the groups most at risk of death or serious illness from Covid-19, glI’m over 70, able to build robust immunity even better than the under 55 age group.
The experimentation does not stop
I volunteers who participated in the clinical trial campaign are more than 23 thousand, 18 years of age and older from various racial and geographic groups who are healthy or with stable underlying medical conditions. Studies are also underway in the United States, Japan, Russia, South Africa, Kenya, and Latin America, with additional studies planned in other European and Asian countries. Throughout, the company plans to test 60,000 volunteers around the world.
When can you get vaccinated
The first two million doses of the vaccine in Italy will be delivered in December and the government has reserved 70 million doses that will be available by June 2021. Nothing will happen before approval by a regulatory body to assess efficacy and safety. AstraZeneca is working towards a production capacity of up to 3 billion doses of the vaccine by 2021.
Are the results disappointing?
After both Pfizer and Moderna have produced vaccines that offer 95% protection against Covid-19, a figure of 70% (which can increase to 90% with a dose change) may seem disappointing despite the WHO already it has done. stated that a vaccine with an effectiveness of more than 50% to be considered a triumph. further This preparation can be stored, transported and handled under normal refrigeration conditions (2-8 degrees) for at least six months and it is administered within existing healthcare facilities, a major advantage over Pfizer and Moderna, which must be stored in cooler temperatures. And another advantage is the ccost: 2.80 euros per dose compared to 16-20 euros for American vaccines.
Next steps
Now AstraZeneca will prepare the documents and data for cask for permits worldwide to authorities who have a framework for conditional or advance approval. The company will also ask the World Health Organization for a list of possibilities to approve it. emergency uses to achieve an accelerated path to vaccine availability in low-income countries. In parallel, the full analysis of the interim results will be submitted for publication in a peer-reviewed journal.
November 23, 2020 (change November 23, 2020 | 10:31)
© REPRODUCTION RESERVED
[ad_2]
